Novel cancer therapies
A diagnosis of cancer still strikes fear into many people. It’s true that some malignancies that would once have been death sentences are becoming more manageable. But, cancer remains a massive threat — it’s the second biggest cause of death, worldwide, killing almost 10 million people annually. And this is the situation after decades of often stunning medical advances. But researchers are closing in on a number of cancer-fighting strategies that are bringing new hope to the millions affected by the disease.
This collection will be updated at the end of May with reporting from journalists.
-
Funded by a grant from:
-
Produced with support from:
Nature is pleased to acknowledge financial support from Pfizer Oncology and grant funding from Merck Sharp & Dohme, Rahway, NJ in producing this Outlook. The sponsor retains sole responsibility for the following message.
About Pfizer Oncology
At Pfizer Oncology, we are at the forefront of a new era in cancer care. Our industry-leading portfolio and extensive pipeline includes game-changing mechanisms of action to attack cancer from multiple angles, including antibody-drug conjugates (ADCs), small molecules, bispecific antibodies and other immunotherapy biologics. We are focused on delivering transformative therapies in some of the world’s most common cancers, including breast cancer, genitourinary cancer, hematology-oncology, and thoracic cancers, which includes lung cancer. Driven by science, we are committed to accelerating breakthroughs that help people with cancer globally live better and longer lives.
